BACKGROUND: Overuse of surveillance testing for breast cancer survivors is an important problem but its extent and determinants are incompletely understood. The objectives of this study were to determine the extent to which physicians' breast cancer surveillance testing beliefs are consistent with test overuse, and to identify factors associated with these beliefs. METHODS: During 2009-2010, a cross-sectional survey of US medical oncologists and primary care physicians (PCPs) was carried out. Physicians responded to a clinical vignette ascertaining beliefs about appropriate breast cancer surveillance testing. Multivariable analyses examined the extent to which test beliefs were consistent with overuse and associated with physician and practice characteristics and physician perceptions, attitudes, and practices. RESULTS: A total of 1098 medical oncologists and 980 PCPs completed the survey (response rate 57.5%). Eighty-four percent of PCPs [95% confidence interval (CI), 81.4%-86.5%] and 72% of oncologists (95% CI, 69.8%-74.7%) reported beliefs consistent with blood test overuse, whereas 50% of PCPs (95% CI, 47.3%-53.8%) and 27% of oncologists (95% CI, 23.9%-29.3%) reported beliefs consistent with imaging test overuse. Among PCPs, factors associated with these beliefs included smaller practice size, lower patient volume, and practice ownership. Among oncologists, factors included older age, international medical graduate status, lower self-efficacy (confidence in knowledge), and greater perceptions of ambiguity (conflicting expert recommendations) regarding survivorship care. CONCLUSIONS: Beliefs consistent with breast cancer surveillance test overuse are common, greater for PCPs and blood tests than for oncologists and imaging tests, and associated with practice characteristics and perceived self-efficacy and ambiguity about testing. These results suggest modifiable targets for efforts to reduce surveillance test overuse.
BACKGROUND: Overuse of surveillance testing for breast cancer survivors is an important problem but its extent and determinants are incompletely understood. The objectives of this study were to determine the extent to which physicians' breast cancer surveillance testing beliefs are consistent with test overuse, and to identify factors associated with these beliefs. METHODS: During 2009-2010, a cross-sectional survey of US medical oncologists and primary care physicians (PCPs) was carried out. Physicians responded to a clinical vignette ascertaining beliefs about appropriate breast cancer surveillance testing. Multivariable analyses examined the extent to which test beliefs were consistent with overuse and associated with physician and practice characteristics and physician perceptions, attitudes, and practices. RESULTS: A total of 1098 medical oncologists and 980 PCPs completed the survey (response rate 57.5%). Eighty-four percent of PCPs [95% confidence interval (CI), 81.4%-86.5%] and 72% of oncologists (95% CI, 69.8%-74.7%) reported beliefs consistent with blood test overuse, whereas 50% of PCPs (95% CI, 47.3%-53.8%) and 27% of oncologists (95% CI, 23.9%-29.3%) reported beliefs consistent with imaging test overuse. Among PCPs, factors associated with these beliefs included smaller practice size, lower patient volume, and practice ownership. Among oncologists, factors included older age, international medical graduate status, lower self-efficacy (confidence in knowledge), and greater perceptions of ambiguity (conflicting expert recommendations) regarding survivorship care. CONCLUSIONS: Beliefs consistent with breast cancer surveillance test overuse are common, greater for PCPs and blood tests than for oncologists and imaging tests, and associated with practice characteristics and perceived self-efficacy and ambiguity about testing. These results suggest modifiable targets for efforts to reduce surveillance test overuse.
Authors: Frank E Johnson; Michael H Johnson; Marc F Clemente; Randal C Paniello; Katherine S Virgo Journal: Ann Surg Oncol Date: 2006-06-21 Impact factor: 5.344
Authors: David M Studdert; Michelle M Mello; William M Sage; Catherine M DesRoches; Jordon Peugh; Kinga Zapert; Troyen A Brennan Journal: JAMA Date: 2005-06-01 Impact factor: 56.272
Authors: Arnold L Potosky; Paul K J Han; Julia Rowland; Carrie N Klabunde; Tenbroeck Smith; Noreen Aziz; Craig Earle; John Z Ayanian; Patricia A Ganz; Michael Stefanek Journal: J Gen Intern Med Date: 2011-07-22 Impact factor: 5.128
Authors: John W Peabody; Jeff Luck; Peter Glassman; Sharad Jain; Joyce Hansen; Maureen Spell; Martin Lee Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: Tenbroeck G Smith; Sara Strollo; Xin Hu; Craig C Earle; Corinne R Leach; Larissa Nekhlyudov Journal: J Gen Intern Med Date: 2019-07-31 Impact factor: 5.128
Authors: Scott D Ramsey; N Lynn Henry; Julie R Gralow; Dana K Mirick; William Barlow; Ruth Etzioni; David Mummy; Rahber Thariani; David L Veenstra Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea Journal: Head Neck Date: 2020-01-10 Impact factor: 3.147
Authors: Betsy C Risendal; Rebecca L Sedjo; Anna R Giuliano; Susan Vadaparampil; Paul B Jacobsen; Kristin Kilbourn; Anna Barón; Tim Byers Journal: J Cancer Surviv Date: 2015-06-13 Impact factor: 4.442
Authors: Jennifer S Haas; Brian L Sprague; Carrie N Klabunde; Anna N A Tosteson; Jane S Chen; Asaf Bitton; Elisabeth F Beaber; Tracy Onega; Jane J Kim; Charles D MacLean; Kimberly Harris; Phillip Yamartino; Kathleen Howe; Loretta Pearson; Sarah Feldman; Phyllis Brawarsky; Marilyn M Schapira Journal: J Gen Intern Med Date: 2016-01 Impact factor: 5.128
Authors: Monica L Zigman Suchsland; Victoria Hardy; Ying Zhang; Patrick D Vigil; Kimberly L Collins; William M Woodhouse; Roger Chou; Steven D Findlay; Danielle C Lavallee; Matthew J Thompson Journal: J Am Board Fam Med Date: 2019 May-Jun Impact factor: 2.657